Kidney Transplantation for the Surgeon — List by Benefit, Anastomose Fast, Watch the Ureter and the Wound

The transplanted kidney wants three verdicts before the knife — whose survival benefit earns an organ, whose donor kidney is worth taking, and whose anastomosis will hold the graft — because benefit beats waiting time, donor risk is priced against healthy donors not populations, and implantation minutes are warm ischaemia that the DCD kidney cannot spare. List by Wolfe mortality with KDIGO candidacy, allocate by KDPI with EPTS matching, consent living donors on matched risk, accept expanded and circulatory-death organs on registry parity, anastomose fast with whatever arteries arrive, stent the ureter and remove it early, read delayed function by its duration, fix the stenosed artery endovascularly, fenestrate the lymphocele, respect the wound, survey virus and antibody, and exchange the incompatible — with every number taken from the papers named beside it.^{[1][26][4][2][9][15]}

A 45-year-old diabetic man waits three years on dialysis; a 32-year-old woman offers her brother a kidney; and a DCD recipient makes no urine on day 3 with a silent graft. One needs benefit-justified listing with longevity-matched allocation, one needs honest donor-risk numbers, and one needs duration-stratified patience with arterial imaging today. The examiner will watch you quote Wolfe against the waitlist, defend KDPI with its discard and disparity arithmetic, consent the donor on matched-healthy risk, price ECD and DCD honestly, time the anastomosis, pull the stent early, separate brief delay from the two-week marker, and stent the stenosed artery — with every number taken from the papers named beside it.^{[1][5][2][7][9][10][18]}

Benefit, donors and implantation are three separate arguments — survival gain for listing, priced risk for donor acceptance, and warm minutes for technique — each with its own validated numbers: Wolfe mortality for candidacy, Muzaale matched risk for living consent, registry parity for DCD, quartile arithmetic for anastomosis time, meta-analytic stent timing for the ureter, and duration thresholds for delayed function.^{[1][2][6][9][16][10]} The strategic arc fits one sentence: prove benefit, match longevity, consent honestly, accept marginal organs on parity, implant fast, stent briefly, wait out short delay, image the silent graft, drain collections laparoscopically, and exchange across incompatibility.^{[1][5][7][9][19][24]}

List by benefit, allocate by longevity

Transplantation buys life against the waitlist, not against dialysis in general: death risk runs 2.8 times higher in the first two weeks after transplantation, falls to 0.32 at 18 months, and settles 48 to 82 percent lower long-term at 3.8 deaths per 100 patient-years — against 6.3 on the waitlist and 16.1 across all dialysis, with the largest gains in the young, white recipients and younger diabetics.^[1] Candidacy is judged whole, not by single bans: the 2020 KDIGO candidate guideline assists teams worldwide across access, demographics, immunology and every comorbidity from adherence to cardiac disease, with each factor weighed separately inside the local context toward one overall judgment, built by GRADE systematic review.^[26] Allocation matches longevity both ways: since December 2014 the KDPI has driven deceased-donor allocation under KAS, and when a programming error inflated scores the discard rate rose only to 22.9 against a projected 31.4 — clinicians refused the single number — though kidneys crossing the 85 percent policy threshold still discarded half as often again.^[4] The match is honoured unevenly: EPTS 20 percent-or-below candidates are prioritised for KDPI 20 percent-or-below kidneys, yet only 49.4 percent of transplanted best-survival candidates received one while 48.3 percent of best kidneys went elsewhere — with the odds lowest in region 9 at 0.19 against region 6, tracking organ availability at 0.84 correlation.^[5]

Take living, expanded and circulatory-death donors — each priced

Living donors pay a small absolute price against the right comparator: ESRD at 15 years runs 30.8 per 10,000 donors against 3.9 per matched healthy nondonors, with lifetime risk at 90 per 10,000 donors against 14 per healthy nondonors and 326 per unscreened population — an increased risk over 7.6 median years whose absolute magnitude stays small.^[2] Donor workup is comprehensive by design: the 2017 KDIGO living-donor guideline replaces single-factor vetoes with whole-profile quantitative risk including a proof-in-concept kidney-failure prediction model, covering evaluation and care before, during and after donation.^[27] Expanded-criteria kidneys trade prognosis for access: across 32 publications with only five adjusted American studies, ECD recipients carry poorer survival — with the European gap narrower than the North American one, especially for death-censored graft failure.^[3] Circulatory-death kidneys earn equal selection: UK registry analyses show higher cold-ischaemia susceptibility and more delayed function, yet short, medium and now longer-term outcomes match brain-death donors — including expanded-criteria DCD against expanded-criteria DBD — so selection criteria should be identical.^[6] The world meta agrees with arithmetic: across 51 studies with 73,454 DCD and 518,229 DBD recipients, one-year graft loss rises a tenth while ten-year loss ties — with primary non-function up 43 percent, delayed function doubled and one-year mortality up a tenth, but rejection, ureter disease, one-year filtration and ten-year mortality all tied.^[7] Machine perfusion stays honest in kidneys: in 338 randomised DCD kidneys, one hour of normothermic perfusion at the end of cold storage left delayed function at 60.7 against 58.5 percent — no reduction — though with no excess thrombosis, infection or adverse events, proving feasibility and safety for clinical use.^[8]

Implant fast with whatever arteries arrive

Anastomosis time is warm ischaemia the surgeon owns: across 6,397 American DCD transplants it averaged two-thirds of total warm time at a 38-minute median — and the longest quartile at 48 minutes or more raised delayed function to 44.0 against 36.7 percent and cut five-year graft survival to 84.8 against 88.2, with graft-failure hazard at 1.21 and no patient-survival cost.^[9] Multiple arteries are no veto in skilled hands: across 208 living-donor grafts only haemorrhage and arterial thrombosis ran higher — with rejection, hypertension, stenosis, urological complications, clearance at one and five years, and patient and graft survival all tied.^[12] Thrombosis is early, devastating and sensitising: defined within 30 days, it strikes women at 2.24 odds and right kidneys at 1.46 — with older age and Asian ethnicity protective — and once sensitisation follows, the chance of retransplantation falls 37 percent with median sensitisation at 288 days.^[13]

Stent the ureter, remove the stent early

Ureter technique rests on equipoise, honestly stated: only three prospective studies with serious or critical bias and low-certainty evidence compare Taguchi against Lich-Gregoir extravesical implantation — so no effect can be determined and randomised long-term trials are owed.^[14] Stent timing is settled where technique is not: across 568 patients in five randomised trials, pulling the stent at 7 days or earlier halved urinary infection at RR 0.43 — with major urological complications of stricture, obstruction and leak tied at RR 1.87 and no significance.^[15] Living donation confirms it: across eight studies with 2,148 recipients, removal before three weeks cut infection at OR 0.53 — with major complications, obstruction and leak each tied — so early removal lowers infection without raising urological harm.^[16]

Read delayed function by duration, fix the stenosed artery

Delayed function is common, modifiable and duration-defined: at 15 percent in one 380-patient deceased-donor cohort, diabetes, ASA-4 status, cold time beyond 13 hours and donor age above 55 each roughly double to triple the odds — while colloids, albumin, crystalloids beyond 3000 mL and reperfusion pressure below 80 mmHg are the intraoperative levers, with pressure above 80 and restrained fluids protective.^[11] Duration, not presence, writes prognosis: across 4,714 British DCD transplants at 39.9 percent delayed function, risk-adjusted graft and patient survival tied overall — but delay beyond 14 days raised death-censored failure at 1.7 and death at 1.8, making prolonged delay the early biomarker of worse years.^[10] The stenosed artery answers endovascularly: across 32 studies with 884 interventions, clinical success runs 65.5 to 94 percent with technical success above 90 — though definitions and follow-up vary so widely that standardised registry reporting is owed.^[17] Stents beat balloons on restenosis alone: at 28 against 8 percent restenosis with deeper immediate luminal gain — yet creatinine, pressure and graft and patient survival tie, so the stent buys patency, not longevity.^[18]

Drain collections, respect the wound

Lymphoceles span nuisance to graft threat: incidence runs 0.6 to 51 percent despite prevention — diagnosed by ultrasound, CT or MRI, fenestrated laparoscopically when conservative care fails, and best prevented by a peritoneal window left at the end of the transplant.^[19] Wound infection is rare and expensive: at 1.9 percent across 3,059 Swiss recipients with BMI 25-or-above and delayed function as independent drivers — it independently carries graft loss at HR 3.75.^[20] The Canadian arithmetic agrees: 4.13 percent cumulative probability at 30 days, driven by BMI, cold ischaemic time and era — with wound complications carrying death-censored failure at 3.08 and total failure at 2.09 plus two thousand dollars of extra cost.^[21]

Survey virus and antibody, exchange the incompatible

BK virus follows immunosuppression intensity: eight drivers led by tacrolimus regimens, deceased donors, male recipients, prior transplants, age, stent use, delayed function and rejection — with tacrolimus and rejection also driving nephropathy itself.^[22] Subclinical antibody rejection rewards surveillance: treated subclinical disease fails at 8 percent like biopsied controls — against 46 percent for clinical rejection — with only clinical rejection and chronicity scores predicting loss, so DSA-monitored early treatment is the strategy.^[23] Exchange multiplies the incompatible: accepting ABO-incompatible donors lifted an Australian paired program from 27 recipients in 12 chains to 48 transplanted across extended chains — aimed at the highly sensitised with median panel reactivity at 83 percent.^[24] Crossing ABO still beats waiting: incompatible living donation costs early mortality at 99.0 against 99.6 percent at 30 days — then pays back at 90.0 and 75.4 percent survival at five and ten years against 81.9 and 68.4 for waiting or compatible grafts.^[25] Rejection classification and drug regimens themselves live with the principles topic — Banff classes, Symphony-based tacrolimus maintenance, induction, minimisation trials and infection prophylaxis are examined there, not here.^[26]

The cohorts behind the numbers run Wolfe 228,552-patient dialysis-to-transplant mortality, Muzaale 96,217-donor ESRD risk, Querard 32-publication ECD meta, Stewart KAS miscalibration month, Husain 121,069-candidate allocation geography, Summers UK DCD registry, Rijkse 51-study DCD meta, Hosgood 338-kidney perfusion RCT, Cron 6,397-graft anastomosis registry, Phillips 4,714-patient DGF-duration cohort, Kaufmann 380-patient DGF risk study, Chabchoub 208-graft multiple-artery series, Adler living-donor thrombosis registry, Wehner three-study ureter review, Cai five-trial stent meta with 568 patients, Kusuma eight-study living-donor stent meta with 2,148 recipients, Ngo 32-study TRAS review with 884 interventions, Chen 82-patient angioplasty-stent comparison, Golriz lymphocele review, Schreiber 3,059-patient SSI cohort, Wong SSC cohort, Demey 34-study BK review, Parajuli 220-biopsy AMR cohort, Ferrari Australian paired-exchange program, Massie 808-patient ABO-incompatible survival, and Chadban-Lentine KDIGO candidate and donor guidelines — randomised where randomisable, registry where allocation lives, meta-analytic where trials are small.^{[1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27]}

Benefit, minutes and duration close the traps: the waitlisted diabetic is listed on mortality gain, not dialysis vintage, since transplantation halves long-term death; the living donor is consented on matched-healthy risk, since populations mislead; the DCD kidney is accepted on parity, since ten-year grafts tie; the anastomosis is hurried, since the longest quartile loses grafts; the stent is pulled within days, since infection halves with complications tied; the silent day-3 graft is imaged for artery and thrombosis, since sensitisation forecloses retransplantation; delay past two weeks is escalated, since duration predicts failure; and the incompatible pair is exchanged, since crossing ABO beats waiting.^{[1][2][7][9][16][13][10][24]}

Allocate KDPI/EPTS exactly: KAS from December 2014 with 85% discard threshold behaviour at 22.9 vs 19.6% (PMID 28556492); EPTS 20% prioritisation with only 49.4% concordance and region-6-vs-9 odds 0.19 (PMID 31506000).^[4] Beat the clock exactly: anastomosis is 67% of warm ischaemia at 38-minute median; longest vs shortest quartile at 44.0 vs 36.7% DGF and 84.8 vs 88.2% 5-year grafts (PMID 35703788).^[24][9] Fix TRAS exactly: 32-study review at 884 interventions with 65.5-94% clinical and >90% technical success but no standard definitions (PMID 26088719); stents restenose 8 vs 28% with survival tied (PMID 29394514).^[17][18]

2.8x death risk in first 2 weeks, 0.32 at 18 months, 48-82% lower long-term mortality at 3.8 per 100 patient-years with waitlist 6.3 vs all-dialysis 16.1 (PMID 10580071).^[1] Concede ureter technique exactly: Taguchi vs Lich-Gregoir rests on 3 biased prospective studies with unclear effect (PMID 34537774); stent early at 7 days or 3 weeks halving UTI at RR 0.43 and OR 0.53 with MUCs tied (PMIDs 30577214/40274763).^[16]

References27ShowHide

1. [1]Wolfe RA, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med, 1999.PMID 10580071
2. [2]Muzaale AD, et al. Risk of end-stage renal disease following live kidney donation. JAMA, 2014.PMID 24519297
3. [3]Querard AH, et al. Comparison of survival outcomes between Expanded Criteria Donor and Standard Criteria Donor kidney transplant recipients: a systematic review and meta-analysis. Transpl Int, 2016.PMID 26756928
4. [4]Stewart DE, et al. New Insights Into the Alleged Kidney Donor Profile Index Labeling Effect on Kidney Utilization. Am J Transplant, 2017.PMID 28556492
5. [5]Husain SA, et al. Regional Disparities in Transplantation With Deceased Donor Kidneys With Kidney Donor Profile Index Less Than 20% Among Candidates With Top 20% Estimated Post Transplant Survival. Prog Transplant, 2019.PMID 31506000
6. [6]Summers DM, et al. Kidney donation after circulatory death (DCD): state of the art. Kidney Int, 2015.PMID 25786101
7. [7]Rijkse E, et al. Implementation of donation after circulatory death kidney transplantation can safely enlarge the donor pool: A systematic review and meta-analysis. Int J Surg, 2021.PMID 34256169
8. [8]Hosgood SA, et al. Normothermic machine perfusion versus static cold storage in donation after circulatory death kidney transplantation: a randomized controlled trial. Nat Med, 2023.PMID 37231075
9. [9]Cron DC, et al. Anastomosis Time and Outcomes after Donation after Circulatory Death Kidney Transplantation. J Am Coll Surg, 2022.PMID 35703788
10. [10]Phillips BL, et al. Effect of delayed graft function on longer-term outcomes after kidney transplantation from donation after circulatory death donors in the United Kingdom: A national cohort study. Am J Transplant, 2021.PMID 33756062
11. [11]Kaufmann KB, et al. Modifiable Risk Factors for Delayed Graft Function After Deceased Donor Kidney Transplantation. Prog Transplant, 2019.PMID 31167610
12. [12]Chabchoub K, et al. Does kidney transplantation with multiple arteries affect graft survival? Transplant Proc, 2011.PMID 22099812
13. [13]Adler JT, et al. Renal allograft thrombosis after living donor transplantation: risk factors and obstacles to retransplantation. Clin Transplant, 2016.PMID 27101358
14. [14]Wehner H, et al. Taguchi versus Lich-Grégoir Extravesical Ureteroneocystostomy in Kidney Transplantation: A Systematic Review. Urol Int, 2021.PMID 34537774
15. [15]Cai JF, et al. Meta-analysis of Early Versus Late Ureteric Stent Removal After Kidney Transplantation. Transplant Proc, 2018.PMID 30577214
16. [16]Kusuma MHH, et al. Early ureteral stent removal reduces urinary tract infection risk without increasing complications in living donor kidney transplantation: a systematic review and meta-analysis. Clin Transplant Res, 2025.PMID 40274763
17. [17]Ngo AT, et al. A Systematic Review of Outcomes Following Percutaneous Transluminal Angioplasty and Stenting in the Treatment of Transplant Renal Artery Stenosis. Cardiovasc Intervent Radiol, 2015.PMID 26088719
18. [18]Chen LX, et al. Angioplasty vs stent in the treatment of transplant renal artery stenosis. Clin Transplant, 2018.PMID 29394514
19. [19]Golriz M, et al. Prevention and management of lymphocele formation following kidney transplantation. Transplant Rev (Orlando), 2017.PMID 28011070
20. [20]Schreiber PW, et al. Surgical site infections after kidney transplantation are independently associated with graft loss. Am J Transplant, 2024.PMID 38042413
21. [21]Wong RBK, et al. Surgical site complications in kidney transplant recipients: incidence, risk factors and outcomes in the modern era. Can J Surg, 2021.PMID 34933944
22. [22]Demey B, et al. Risk factors for BK virus viremia and nephropathy after kidney transplantation: A systematic review. J Clin Virol, 2018.PMID 30343190
23. [23]Parajuli S, et al. Subclinical Antibody-mediated Rejection After Kidney Transplantation: Treatment Outcomes. Transplantation, 2019.PMID 30507740
24. [24]Ferrari P, et al. ABO-incompatible matching significantly enhances transplant rates in kidney paired donation. Transplantation, 2013.PMID 23860086
25. [25]Massie AB, et al. Impact of ABO-Incompatible Living Donor Kidney Transplantation on Patient Survival. Am J Kidney Dis, 2020.PMID 32668318
26. [26]Chadban SJ, et al. KDIGO Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation. Transplantation, 2020.PMID 32301874
27. [27]Lentine KL, et al. KDIGO Clinical Practice Guideline on the Evaluation and Care of Living Kidney Donors. Transplantation, 2017.PMID 28742762